Muneer A. Satter, who serves as a director at Annexon, Inc. (NASDAQ:ANNX), recently acquired a significant block of the company's common stock. On May 28, 2026, Mr. Satter purchased 613,497 shares of ANNX for $5.41 per share, resulting in a total expenditure of approximately $3,319,018.
The acquisition was structured through Alerce Medical Technology Partners, L.P., meaning the purchase was indirect. Despite this structure, Mr. Satter retains sole voting and dispositive power over these acquired shares. Following this transaction, his total indirect holdings of Annexon, Inc. common stock rose to 10,342,134 shares. It is important to note that Mr. Satter disclaimed beneficial ownership of the shares except to the extent of his pecuniary interest.
This notable buying activity takes place while ANNX shares are trading near $5.42. The stock has demonstrated considerable momentum over the past year, recording a 146% return. Furthermore, analysis provided by InvestingPro suggests that the stock may currently be slightly undervalued at its present price levels.
From a financial perspective, InvestingPro Tips point out specific strengths in the company's balance sheet and development pipeline: Annexon holds more cash than debt. Additionally, four separate analysts have recently revised their earnings estimates upward. These details contribute to an overall picture of internal confidence within the company's management and its strategic positioning.
Beyond the director’s purchase, Annexon Biosciences has attracted considerable attention from various analyst firms, each offering a distinct perspective on the company's trajectory. This divergence reflects both cautious optimism regarding key treatments and specific commercial uncertainties.
Goldman Sachs initiated coverage of the firm with a Neutral rating and established a price target of $7.00. The bank cited uncertainty surrounding Annexon’s ongoing geographic atrophy trial as a primary reason for its measured outlook. In contrast, Jefferies reiterated a Buy rating and set a price target of $10.00. This bullish view was supported by highlighting recent merger and acquisition activity within the complement inhibitor sector. Specifically, the article points to Biogen's acquisition of Apellis Pharmaceuticals as an indicator of growing interest from major pharmaceutical companies in this therapeutic area.
Further strengthening the positive sentiment, H.C. Wainwright maintained its Buy rating while simultaneously elevating its price target to $14.00. This firm emphasized the unique characteristics and design of Annexon’s Phase 3 trial for vonaprument, which is designed to treat geographic atrophy. These varied analyst reports collectively showcase a spectrum of views, ranging from cautious assessment to strong strategic interest in Annexon's ongoing research projects.
The market data also provides additional context: the stock closed at $5.81 and was trading up 7.20% after hours, while its intraday movement showed gains of 0.93%. This suggests active investor participation following the reporting period.